Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.8 EUR | -1.75% | +1.45% | -23.50% |
May. 28 | BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
Apr. 16 | Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery | MT |
Sales 2024 * | 62.56M 67.85M | Sales 2025 * | 70.97M 76.97M | Capitalization | 61.17M 66.34M |
---|---|---|---|---|---|
Net income 2024 * | -3M -3.25M | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.37 x |
Net Debt 2024 * | 24.73M 26.82M | Net Debt 2025 * | 23.42M 25.4M | EV / Sales 2025 * | 1.19 x |
P/E ratio 2024 * |
-17.5
x | P/E ratio 2025 * |
-161
x | Employees | 311 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.38% |
Latest transcript on BRAIN Biotech AG
1 day | -1.75% | ||
1 week | +1.45% | ||
3 months | -28.57% | ||
6 months | -18.13% | ||
Current year | -23.50% |
Managers | Title | Age | Since |
---|---|---|---|
Adriaan Moelker
CEO | Chief Executive Officer | 60 | 20-01-31 |
Director of Finance/CFO | 54 | 20-04-30 | |
Alexander Pelzer
CTO | Chief Tech/Sci/R&D Officer | 38 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Majerus
CHM | Chairman | 63 | 19-03-06 |
Stephen Catling
BRD | Director/Board Member | 59 | 20-10-13 |
Director/Board Member | 70 | 20-10-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.8 | -1.75% | 6,312 |
24-05-30 | 2.85 | -1.72% | 34,546 |
24-05-29 | 2.9 | +2.84% | 30,324 |
24-05-28 | 2.82 | +1.81% | 27,239 |
24-05-27 | 2.77 | +0.36% | 8,037 |
Delayed Quote Xetra, May 31, 2024 at 11:36 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.50% | 66.34M | |
-27.23% | 222M | |
+30.98% | 73.37M |
- Stock Market
- Equities
- BNN Stock